Nanobiotix S.A. (0QAV.L)
0QAV.L Stock Price Chart
Explore Nanobiotix S.A. interactive price chart. Choose custom timeframes to analyze 0QAV.L price movements and trends.
0QAV.L Company Profile
Discover essential business fundamentals and corporate details for Nanobiotix S.A. (0QAV.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
13 Feb 2014
Employees
108.00
Website
https://www.nanobiotix.comCEO
Laurent Levy
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
0QAV.L Financial Timeline
Browse a chronological timeline of Nanobiotix S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 May 2026
Upcoming earnings on 10 Nov 2025
Earnings released on 2 Apr 2025
EPS came in at -€0.98 falling short of the estimated -€0.53 by -83.21%, while revenue for the quarter reached -€20.90M, missing expectations by -742.55%.
Earnings released on 12 Nov 2024
EPS came in at -€0.46 falling short of the estimated -€0.46 by -0.90%, while revenue for the quarter reached €9.29M, missing expectations by -0.12%.
Earnings released on 22 May 2024
EPS came in at -€0.30 surpassing the estimated -€0.75 by +60.15%, while revenue for the quarter reached €32.92M.
Earnings released on 30 Jun 2023
EPS came in at -€0.80 falling short of the estimated -€0.54 by -48.51%, while revenue for the quarter reached €3.29M, missing expectations by -8.53%.
Earnings released on 31 Dec 2022
EPS came in at -€0.88, while revenue for the quarter reached €3.45M.
Earnings released on 30 Jun 2022
EPS came in at -€0.76, while revenue for the quarter reached €1.33M.
Dividend declared on 15 Mar 2022
A dividend of €0.29 per share was announced, adjusted to €0.29.
Earnings released on 31 Dec 2021
EPS came in at -€0.48 surpassing the estimated -€0.81 by +41.19%, while revenue for the quarter reached €1.33M, beating expectations by +10.67%.
Earnings released on 30 Jun 2021
EPS came in at -€0.88 falling short of the estimated -€0.70 by -25.53%, while revenue for the quarter reached €10.00K, beating expectations by +3.09%.
Earnings released on 31 Dec 2020
EPS came in at -€0.47 surpassing the estimated -€0.82 by +43.02%, while revenue for the quarter reached €13.00K, beating expectations by -966.67%.
0QAV.L Stock Performance
Access detailed 0QAV.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.